
## Carolyn S P Lam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8092300/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
2	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	13.9	2,143
3	The Global Health and Economic Burden ofÂHospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133.	1.2	1,640
4	Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	13.9	1,485
5	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2009, 53, 1119-1126.	1.2	1,160
6	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	1.0	944
7	Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2010, 3, 588-595.	1.6	891
8	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
9	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	13.9	753
10	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
11	Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2010, 56, 845-854.	1.2	606
12	Epidemiology and clinical course of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2011, 13, 18-28.	2.9	569
13	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet, The, 2021, 397, 2385-2438.	6.3	530
14	Cardiac Structure and Ventricular–Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota. Circulation, 2007, 115, 1982-1990.	1.6	475
15	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 653-662.	5.5	437
16	Noncardiac Comorbidities in HeartÂFailureÂWith Reduced Versus PreservedÂEjection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293.	1.2	424
17	Sex differences in heart failure. European Heart Journal, 2019, 40, 3859-3868c.	1.0	406
18	Age-Associated Increases in Pulmonary Artery Systolic Pressure in the General Population. Circulation, 2009, 119, 2663-2670.	1.6	384

#	Article	IF	CITATIONS
19	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. European Heart Journal, 2018, 39, 3439-3450.	1.0	375
20	Contractility and Ventricular Systolic Stiffening in Hypertensive Heart Disease. Journal of the American College of Cardiology, 2009, 54, 410-418.	1.2	372
21	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology, 2018, 71, 2628-2639.	1.2	370
22	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
23	Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 896-907.	13.9	339
24	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	1.0	304
25	Sex Differences in Cardiovascular Pathophysiology. Circulation, 2018, 138, 198-205.	1.6	302
26	Heart failure with midâ€range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 2018, 20, 1230-1239.	2.9	295
27	Heart Failure With Preserved EjectionÂFraction andÂAtrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.	1.2	292
28	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American Journal of Hematology, 2017, 92, 1068-1078.	2.0	290
29	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	3.8	288
30	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	1.0	285
31	Cardiac Dysfunction and Noncardiac Dysfunction as Precursors of Heart Failure With Reduced and Preserved Ejection Fraction in the Community. Circulation, 2011, 124, 24-30.	1.6	274
32	Developing Therapies for Heart Failure WithÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	1.9	267
33	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. New England Journal of Medicine, 2018, 379, 1332-1342.	13.9	265
34	Pulmonary Pressures and Death in Heart Failure. Journal of the American College of Cardiology, 2012, 59, 222-231.	1.2	250
35	Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal, 2018, 39, 2780-2792.	1.0	250
36	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244

#	Article	IF	CITATIONS
37	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. European Journal of Heart Failure, 2016, 18, 588-598.	2.9	242
38	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	2.9	239
39	Angiotensin Receptor Neprilysin InhibitionÂin Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2017, 5, 471-482.	1.9	238
40	Right ventricular dysfunction in leftâ€sided heart failure with preserved versus reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 1664-1671.	2.9	224
41	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349.	1.6	217
42	Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1). Chest, 2014, 146, 1274-1285.	0.4	214
43	Left Ventricular Function and Exercise Capacity. JAMA - Journal of the American Medical Association, 2009, 301, 286.	3.8	208
44	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2016, 18, 1472-1487.	2.9	200
45	Heart Failure Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. PLoS Medicine, 2014, 11, e1001699.	3.9	198
46	A comprehensive populationâ€based characterization of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2017, 19, 1624-1634.	2.9	196
47	Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. Circulation, 2020, 141, 540-548.	1.6	195
48	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	2.9	195
49	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. European Heart Journal, 2018, 39, 1770-1780.	1.0	194
50	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	2.9	193
51	Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart, 2011, 97, 964-969.	1.2	191
52	Sexâ€specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 535-542.	2.9	184
53	Growth differentiation factor 15, ST2, highâ€sensitivity troponin T, and Nâ€ŧerminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. European Journal of Heart Failure, 2012, 14, 1338-1347.	2.9	181
54	How do patients with heart failure with preserved ejection fraction die?. European Journal of Heart Failure, 2013, 15, 604-613.	2.9	178

#	Article	IF	CITATIONS
55	Heart failure with preserved ejection fraction: a clinical dilemma. European Heart Journal, 2014, 35, 1022-1032.	1.0	178
56	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2012, 5, 571-578.	1.6	177
57	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	1.6	177
58	The middle child in heart failure: heart failure with midâ€range ejection fraction (40–50%). European Journal of Heart Failure, 2014, 16, 1049-1055.	2.9	172
59	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512.	3.8	170
60	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.4	163
61	Sodiumâ€Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e014908.	1.6	161
62	Circulating <scp>microRNAs</scp> in heart failure with reduced and preserved left ventricular ejection fraction. European Journal of Heart Failure, 2015, 17, 393-404.	2.9	160
63	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, The, 2019, 394, 1254-1263.	6.3	159
64	Aortic Root Remodeling Over the Adult Life Course. Circulation, 2010, 122, 884-890.	1.6	155
65	Familial hypercholesterolaemia: A global call to arms. Atherosclerosis, 2015, 243, 257-259.	0.4	148
66	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. European Heart Journal, 2016, 37, 3141-3153.	1.0	144
67	Cardiac Natriuretic Peptides, Obesity, and Insulin Resistance: Evidence from Two Community-Based Studies. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3242-3249.	1.8	141
68	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the EfficacyÂand Safety of the Oral Soluble Guanylate Cyclase Stimulator. JACC: Heart Failure, 2018, 6, 96-104.	1.9	141
69	The potential role and rationale for treatment of heart failure with sodium–glucose coâ€ŧransporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	2.9	139
70	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 1303-1311.	2.9	138
71	Echocardiographic Features of PatientsÂWith HeartÂFailure and PreservedÂLeft Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2858-2873.	1.2	138
72	Influence of Sex and Hormone Status on Circulating Natriuretic Peptides. Journal of the American College of Cardiology, 2011, 58, 618-626.	1.2	136

#	Article	IF	CITATIONS
73	Heart failure with reduced ejection fraction. Nature Reviews Disease Primers, 2017, 3, 17058.	18.1	136
74	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 92-98.	1.9	129
75	Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. European Journal of Heart Failure, 2016, 18, 81-88.	2.9	128
76	Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. European Heart Journal, 2015, 36, 2050-2060.	1.0	126
77	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. Cell, 2019, 179, 736-749.e15.	13.5	126
78	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction ChangeÂin HeartÂFailure. JACC: Heart Failure, 2019, 7, 306-317.	1.9	125
79	Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population. Journal of the American College of Cardiology, 2007, 49, 1193-1202.	1.2	122
80	Rationale and design of the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE</scp> Studies ( <scp>SOCRATES</scp> ). European Journal of Heart Failure, 2014, 16, 1026-1038.	2.9	119
81	SGLTâ€2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. Journal of the American Heart Association, 2019, 8, e013389.	1.6	119
82	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	1.6	117
83	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 2029-2044.	1.6	117
84	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. Journal of the American College of Cardiology, 2015, 65, 1668-1682.	1.2	116
85	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2022, 10, 73-84.	1.9	115
86	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	1.0	114
87	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. The Lancet Global Health, 2018, 6, e1008-e1018.	2.9	113
88	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project. European Journal of Preventive Cardiology, 2017, 24, 1637-1645.	0.8	109
89	Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. European Journal of Heart Failure, 2018, 20, 738-747.	2.9	109
90	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovascular Research, 2021, 117, 2108-2124.	1.8	108

#	Article	IF	CITATIONS
91	Iron deficiency in a multiâ€ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. European Journal of Heart Failure, 2014, 16, 1125-1132.	2.9	104
92	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. Journal of Controlled Release, 2017, 247, 127-133.	4.8	104
93	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. The Lancet Global Health, 2020, 8, e411-e422.	2.9	104
94	Heart failure with preserved ejection fraction in Asia. European Journal of Heart Failure, 2019, 21, 23-36.	2.9	102
95	Risk Factors for Heart Failure. Circulation: Heart Failure, 2020, 13, e006472.	1.6	100
96	Age-Related Characteristics and Outcomes of Patients With HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 601-612.	1.2	97
97	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Medicine, 2018, 15, e1002541.	3.9	97
98	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2018, 19, 425-432.	0.5	93
99	Characterization of the <scp>inflammatoryâ€metabolic</scp> phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. European Journal of Heart Failure, 2020, 22, 1551-1567.	2.9	93
100	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European Journal of Heart Failure, 2018, 20, 1664-1672.	2.9	92
101	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
102	Heart failure in Southeast Asia: facts and numbers. ESC Heart Failure, 2015, 2, 46-49.	1.4	89
103	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 2017, 19, 1651-1660.	2.9	89
104	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. JACC: Heart Failure, 2020, 8, 931-939.	1.9	88
105	Patientâ€reported outcomes in the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE patientS</scp> with <scp>PRESERVED</scp> ejection fraction ( <scp>SOCRATESâ€PRESERVED</scp> ) study. European Journal of Heart Failure, 2017, 19, 782-791.	2.9	84
106	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchâ€. European Heart Journal, 2017, 38, ehw597.	1.0	83
107	Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ, The, 2021, 372, n461.	3.0	83
108	20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health, The, 2019, 4, e406-e420.	4.7	82

#	Article	IF	CITATIONS
109	Sex Differences in Heart Failure WithÂPreserved Ejection FractionÂPathophysiology. JACC: Heart Failure, 2019, 7, 239-249.	1.9	82
110	Circulating Insulin-Like Growth Factor-1 and Its Binding Protein-3. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1479-1484.	1.1	81
111	Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. Circulation, 2020, 141, 4-6.	1.6	81
112	Asian Sudden Cardiac Death in Heart Failure (ASIANâ€HF) registry. European Journal of Heart Failure, 2013, 15, 928-936.	2.9	78
113	Endothelial Dysfunction. Journal of the American College of Cardiology, 2012, 60, 1787-1789.	1.2	77
114	Health-Related Quality of Life in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2019, 7, 862-874.	1.9	77
115	Correlation of the New York Heart Association Classification and the 6â€Minute Walk Distance: A Systematic Review. Clinical Cardiology, 2015, 38, 621-628.	0.7	76
116	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.	1.9	75
117	Mineralocorticoid Accelerates Transition to Heart Failure With Preserved Ejection Fraction Via "Nongenomic Effects†Circulation, 2010, 122, 370-378.	1.6	74
118	The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 1638-1647.	2.9	74
119	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	1.5	74
120	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. Journal of the American College of Cardiology, 2021, 78, 142-152.	1.2	74
121	Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 2021, 42, 3741-3752.	1.0	74
122	Left atrial function in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2020, 22, 472-485.	2.9	71
123	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 983-991.	2.9	70
124	Variable phenotype in murine transverse aortic constriction. Cardiovascular Pathology, 2012, 21, 188-198.	0.7	69
125	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. Journal of the American Heart Association, 2019, 8, e013114.	1.6	69
126	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 2019, 40, 3593-3602.	1.0	69

#	Article	IF	CITATIONS
127	Effects of Interatrial Shunt on Pulmonary Vascular Function in HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2539-2550.	1.2	69
128	International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered OutcomesÂMeasurement Set for HeartÂFailure Patients. JACC: Heart Failure, 2020, 8, 212-222.	1.9	69
129	Combining Circulating MicroRNA andÂNT-proBNP to Detect and CategorizeÂHeart Failure Subtypes. Journal of the American College of Cardiology, 2019, 73, 1300-1313.	1.2	68
130	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Human Molecular Genetics, 2011, 20, 1241-1251.	1.4	67
131	What have we learned about heart failure with midâ€range ejection fraction one year after its introduction?. European Journal of Heart Failure, 2017, 19, 1569-1573.	2.9	67
132	World Heart Federation Roadmap for Heart Failure. Global Heart, 2019, 14, 197.	0.9	67
133	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 606-615.	5.5	67
134	Acute and Chronic Ventricular-Arterial Coupling in Systole and Diastole. Hypertension, 2007, 50, 503-511.	1.3	66
135	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. Journal of Cardiac Failure, 2018, 24, 177-185.	0.7	65
136	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgB	T /Qverloc	k 10 Tf 50 38
137	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	1.0	65
138	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. European Heart Journal, 2021, 42, 4420-4430.	1.0	65
139	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. PLoS Medicine, 2019, 16, e1002916.	3.9	64
140	Singapore's health-care system: key features, challenges, and shifts. Lancet, The, 2021, 398, 1091-1104.	6.3	64
141	Prognostic Utility of Metabolic Exercise Testing in Minimally Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 109, 1494-1498.	0.7	63
142	Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. Circulation, 2020, 141, 530-539.	1.6	62
143	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. The Lancet Digital Health, 2022, 4, e46-e54.	5.9	62
144	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design. Journal of Cardiac Failure, 2013, 19, 156-162.	0.7	61

#	Article	IF	CITATIONS
145	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. European Heart Journal, 2013, 34, 676-683.	1.0	59
146	Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart, 2016, 102, 257-259.	1.2	59
147	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 2020, 22, 898-901.	2.9	59
148	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022, 145, 565-574.	1.6	59
149	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> ( <scp>Vericiguat</scp> Global Study in) Tj ETQq1 1 C	.78249314 r	gB <b>≣</b> \$Overlo <mark>c</mark> t
150	Prevalence and Clinical Significance ofÂDiabetes in Asian Versus White PatientsÂWith Heart Failure. JACC: Heart Failure, 2017, 5, 14-24.	1.9	57
151	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712.	1.6	57
152	Heart failure around the world. European Journal of Heart Failure, 2019, 21, 1187-1196.	2.9	56
153	Classification of HeartÂFailure According to Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 3217-3225.	1.2	56
154	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIANâ€HF Registry. Journal of the American Heart Association, 2020, 9, e012199.	1.6	55
155	Aortic Root Remodeling and Risk of Heart Failure in the Framingham Heart Study. JACC: Heart Failure, 2013, 1, 79-83.	1.9	54
156	Obese Heart Failure With Preserved Ejection Fraction Phenotype. Circulation, 2017, 136, 20-23.	1.6	54
157	Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. Diabetes and Vascular Disease Research, 2015, 12, 234-238.	0.9	53
158	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381.	1.9	53
159	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. JAMA Cardiology, 2021, 6, 706.	3.0	53
160	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORTâ€HF): rationale for and design of a global registry. European Journal of Heart Failure, 2015, 17, 527-533.	2.9	52
161	Heart Failure With Preserved Ejection Fraction in the Young. Circulation, 2018, 138, 2763-2773.	1.6	52
162	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. Diabetes Care, 2019, 42, 1792-1799.	4.3	52

#	Article	IF	CITATIONS
163	Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized <sup>13</sup> C magnetic resonance spectroscopy study. Diabetes, Obesity and Metabolism, 2019, 21, 357-365.	2.2	52
164	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. JAMA Cardiology, 2019, 4, 515.	3.0	51
165	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiology, 2020, 5, 401.	3.0	51
166	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial ( <scp>VALIANT</scp> ). European Journal of Heart Failure, 2015, 17, 301-312.	2.9	50
167	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. European Journal of Heart Failure, 2020, 22, 1147-1155.	2.9	50
168	Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. JACC: Heart Failure, 2016, 4, 502-510.	1.9	49
169	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	1.9	48
170	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875.	1.0	47
171	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. European Heart Journal, 2020, 41, 1357-1364.	1.0	47
172	The mitral L wave: A marker of pseudonormal filling and predictor of heart failure in patients with left ventricular hypertrophy. Journal of the American Society of Echocardiography, 2005, 18, 336-341.	1.2	46
173	The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. Expert Review of Molecular Diagnostics, 2015, 15, 1577-1588.	1.5	46
174	Systolic Blood Pressure in HeartÂFailure With Preserved Ejection Fraction TreatedÂWith Sacubitril/Valsartan. Journal of the American College of Cardiology, 2020, 75, 1644-1656.	1.2	46
175	Light to Moderate Habitual Alcohol Consumption Is Associated with Subclinical Ventricular and Left Atrial Mechanical Dysfunction in an Asymptomatic Population: Dose-Response and Propensity Analysis. Journal of the American Society of Echocardiography, 2016, 29, 1043-1051.e4.	1.2	45
176	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership. Journal of the American College of Cardiology, 2021, 77, 2960-2972.	1.2	45
177	Iron deficiency in chronic heart failure: caseâ€based practical guidance. ESC Heart Failure, 2018, 5, 764-771.	1.4	43
178	Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1770-1780.	1.6	43
179	Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure. ESC Heart Failure, 2020, 7, 1956-1965.	1.4	43
180	Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular endâ€diastolic pressure. European Journal of Heart Failure, 2017, 19, 1483-1490.	2.9	42

#	Article	IF	CITATIONS
181	Resting and exercise haemodynamics in relation to sixâ€minute walk test in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 715-722.	2.9	41
182	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	2.9	41
183	Bedside Assessment of Cardiac Hemodynamics: The Impact of Noninvasive Testing and Examiner Experience. American Journal of Medicine, 2011, 124, 1051-1057.	0.6	40
184	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. Circulation, 2020, 141, 1915-1926.	1.6	40
185	Statin associated lower cancer risk and related mortality in patients with heart failure. European Heart Journal, 2021, 42, 3049-3059.	1.0	40
186	GuÃa ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
187	Race-Related Differences in LeftÂVentricular Structural and FunctionalÂRemodeling in ResponseÂtoÂIncreased Afterload. JACC: Heart Failure, 2017, 5, 157-165.	1.9	38
188	Fussing Over the Middle Child. Circulation, 2017, 135, 1279-1280.	1.6	38
189	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	38
190	Serum ferritin and risk for newâ€onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017, 19, 348-356.	2.9	38
191	Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. European Journal of Heart Failure, 2020, 22, 646-660.	2.9	38
192	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	1.0	38
193	Singleâ€dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placeboâ€controlled study (PRACTICEâ€ASIAâ€HF). ESC Heart Failure, 2018, 5, 344-353.	1.4	37
194	The Upcoming Epidemic of Heart Failure in South Asia. Circulation: Heart Failure, 2020, 13, e007218.	1.6	37
195	Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. Journal of Alzheimer's Disease, 2016, 50, 27-40.	1.2	36
196	Understanding Heart Failure With Mid-Range Ejection Fraction â^—. JACC: Heart Failure, 2016, 4, 473-476.	1.9	36
197	Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIANâ€HF registry. European Journal of Heart Failure, 2019, 21, 297-307.	2.9	36
198	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. European Journal of Heart Failure, 2020, 22, 834-844.	2.9	36

#	Article	IF	CITATIONS
199	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 2021, 32, 100739.	3.2	36
200	Size, Shape, and Stamina. Hypertension, 2010, 55, 1143-1149.	1.3	35
201	Understanding Contemporary Use of Thiazolidinediones. Circulation: Heart Failure, 2019, 12, e005855.	1.6	35
202	Particulate air pollution on cardiovascular mortality in the tropics: impact on the elderly. Environmental Health, 2019, 18, 34.	1.7	35
203	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> trial. European Journal of Heart Failure, 2021, 23, 1300-1312.	2.9	35
204	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. American Heart Journal, 2014, 168, 142-149.	1.2	34
205	Heart failure with preserved ejection fraction in hypertension. Current Opinion in Cardiology, 2016, 31, 410-416.	0.8	33
206	Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998.	1.6	33
207	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 321-332.	1.9	33
208	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). Clinical Chemistry and Laboratory Medicine, 2019, 57, 633-640.	1.4	33
209	Remote monitoring and digital health tools in CVD management. Nature Reviews Cardiology, 2021, 18, 457-458.	6.1	33
210	Effect of Monocyte-to-Lymphocyte Ratio on Heart Failure Characteristics and Hospitalizations in a Coronary Angiography Cohort. American Journal of Cardiology, 2017, 120, 911-916.	0.7	32
211	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	1.9	32
212	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. American Heart Journal, 2017, 191, 75-81.	1.2	31
213	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. European Journal of Heart Failure, 2020, 22, 1065-1075.	2.9	31
214	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. European Heart Journal, 2020, 41, 2353-2355.	1.0	31
215	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. Scientific Reports, 2021, 11, 4885.	1.6	31
216	Extracellular Vesicle Proteins Associated with Systemic Vascular Events Correlate with Heart Failure: An Observational Study in a Dyspnoea Cohort. PLoS ONE, 2016, 11, e0148073.	1.1	31

#	Article	IF	CITATIONS
217	Chronic Rejection of Cardiac Allografts Is Associated With Increased Lymphatic Flow and Cellular Trafficking. Circulation, 2018, 137, 488-503.	1.6	30
218	Epicardial fat in heart failure with reduced versus preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 835-838.	2.9	30
219	Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509.	2.9	30
220	Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100. Journal of Molecular and Cellular Cardiology, 2015, 82, 13-21.	0.9	29
221	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). American Heart Journal, 2018, 203, 25-29.	1.2	29
222	A porcine model of heart failure with preserved ejection fraction: magnetic resonance imaging and metabolic energetics. ESC Heart Failure, 2020, 7, 93-103.	1.4	29
223	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. Journal of Cardiac Failure, 2020, 26, 1016-1021.	0.7	29
224	A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal, 2021, 42, 1464-1475.	1.0	29
225	Associations of obesity and malnutrition with cardiac remodeling and cardiovascular outcomes in Asian adults: A cohort study. PLoS Medicine, 2021, 18, e1003661.	3.9	29
226	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 35-45.	5.5	29
227	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology, 2020, 109, 331-338.	1.5	28
228	A network analysis to identify pathophysiological pathways distinguishing ischaemic from nonâ€ischaemic heart failure. European Journal of Heart Failure, 2020, 22, 821-833.	2.9	28
229	Heart Failure Subtypes and Cardiomyopathies in Women. Circulation Research, 2022, 130, 436-454.	2.0	28
230	Racial Differences in Electrocardiographic Characteristics and Prognostic Significance in Whites Versus Asians. Journal of the American Heart Association, 2016, 5, e002956.	1.6	27
231	Coronary Sarcoidosis Presenting as Acute Coronary Syndrome. Clinical Cardiology, 2009, 32, E68-71.	0.7	26
232	Cardiac Structural Remodeling, Longitudinal Systolic Strain, and Torsional Mechanics in Lean and Nonlean Dysglycemic Chinese Adults. Circulation: Cardiovascular Imaging, 2018, 11, e007047.	1.3	26
233	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than Nâ€ŧerminal proâ€Bâ€ŧype natriuretic peptide and highâ€sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	2.9	26
234	Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACTâ€ <b>i</b> HF randomized clinical trial. ESC Heart Failure, 2020, 7, 3881-3890.	1.4	26

#	Article	IF	CITATIONS
235	Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 1346-1356.	2.9	26
236	Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. Cardiovascular Research, 2019, 115, 1791-1803.	1.8	25
237	Distinct Pathological Pathways in Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2020, 8, 234-242.	1.9	25
238	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	1.6	25
239	Seipin Knockout Mice Develop HeartÂFailure With Preserved EjectionÂFraction. JACC Basic To Translational Science, 2019, 4, 924-937.	1.9	24
240	Evaluation of highâ€sensitivity Câ€reactive protein and uric acid in vericiguatâ€treated patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1675-1683.	2.9	24
241	Effects of combined renin–angiotensin–aldosterone system inhibitor and betaâ€blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTATâ€CHF</scp> and <scp>ASIANâ€HF</scp> registries. European Journal of Heart Failure, 2020, 22, 1472-1482.	2.9	24
242	The relationship between renal impairment and left ventricular structure, function, and ventricular–arterial interaction in hypertension. Journal of Hypertension, 2011, 29, 1829-1836.	0.3	23
243	Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. Scientific Reports, 2017, 7, 9193.	1.6	23
244	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e004540.	1.6	23
245	Multiâ€ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HFâ€ACTION trial and the ASIANâ€HF registry. European Journal of Heart Failure, 2018, 20, 1281-1289.	2.9	23
246	Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles. International Journal of Molecular Sciences, 2018, 19, 94.	1.8	23
247	Cardiovascular disease and multimorbidity: A call for interdisciplinary research and personalized cardiovascular care. PLoS Medicine, 2018, 15, e1002545.	3.9	23
248	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. Journal of the American College of Cardiology, 2021, 78, 1587-1598.	1.2	23
249	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. Journal of the American Heart Association, 2021, 10, e021094.	1.6	23
250	Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. Heart, 2019, 105, 842-847.	1.2	22
251	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2224-2234.	1.0	22
252	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. European Journal of Heart Failure, 2015, 17, 135-143.	2.9	21

#	Article	IF	CITATIONS
253	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry <sup>®</sup> . Journal of the American Heart Association, 2017, 6, .	1.6	21
254	Influenza-Associated Hospitalizations for Cardiovascular Diseases in the Tropics. American Journal of Epidemiology, 2017, 186, 202-209.	1.6	21
255	Prevalence, clinical correlates, and outcomes of anaemia in multiâ€ethnic Asian patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2018, 5, 570-578.	1.4	21
256	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Clinical Chemistry, 2019, 65, 1221-1227.	1.5	21
257	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499.	1.6	21
258	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. ESC Heart Failure, 2021, 8, 4572-4583.	1.4	21
259	Integrating High-Sensitivity Troponin T andÂSacubitril/Valsartan Treatment inÂHFpEF. JACC: Heart Failure, 2021, 9, 627-635.	1.9	21
260	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. Journal of Cardiac Failure, 2021, 27, 756-765.	0.7	20
261	NT-proBNP for Risk Prediction in HeartÂFailure. JACC: Heart Failure, 2021, 9, 653-663.	1.9	20
262	Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure. Circulation: Cardiovascular Genetics, 2010, 3, 492-498.	5.1	19
263	High-Sensitivity Sandwich ELISA for Plasma NT-proUcn2: Plasma Concentrations and Relationship to Mortality in Heart Failure. Clinical Chemistry, 2016, 62, 856-865.	1.5	19
264	LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. International Journal of Cardiology, 2018, 271, 247-253.	0.8	19
265	Revisiting methods for assessing and comparing left ventricular diastolic stiffness: impact of relaxation, external forces, hypertrophy, and comparators. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2738-H2746.	1.5	18
266	The Socioeconomics of Hypertension. Hypertension, 2011, 58, 140-141.	1.3	18
267	Asia-Pacific consensus statement on the optimal use of high-sensitivity troponin assays in acute coronary syndromes diagnosis: focus on hs-Tnl. Heart Asia, 2017, 9, 81-87.	1.1	18
268	Obesity-Related Changes in Cardiac Structure and Function Among Asian Men and Women. Journal of the American College of Cardiology, 2017, 69, 2876-2878.	1.2	18
269	Application of the H <sub>2</sub> FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2019, 21, 1288-1291.	2.9	18
270	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International Journal of Cardiology, 2020, 318, 126-129.	0.8	18

#	Article	IF	CITATIONS
271	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
272	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <scp>REPORTâ€HF</scp> registry. European Journal of Heart Failure, 2022, 24, 645-652.	2.9	18
273	Atrial Fibrillation in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 336-346.	1.9	18
274	Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. Journal of Cardiac Failure, 2017, 23, 63-71.	0.7	17
275	Gender-differences in the associations between circulating creatine kinase, blood pressure, body mass and non-alcoholic fatty liver disease in asymptomatic asians. PLoS ONE, 2017, 12, e0179898.	1.1	17
276	Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review. International Journal of Cardiology, 2018, 263, 88-93.	0.8	17
277	A Populationâ€wide study of electrocardiographic (ECG) norms and the effect of demographic and anthropometric factors on selected ECG characteristics in young, Southeast Asian males—results from the Singapore Armed Forces ECG (SAFE) study. Annals of Noninvasive Electrocardiology, 2019, 24, e12634.	0.5	17
278	Extracellular vesicle Cystatin C and CD14 are associated with both renal dysfunction and heart failure. ESC Heart Failure, 2020, 7, 2240-2249.	1.4	17
279	Contemporary economic burden in a realâ€world heart failure population with Commercial and Medicare supplemental plans. Clinical Cardiology, 2021, 44, 646-655.	0.7	17
280	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation, 2019, 140, 1359-1361.	1.6	16
281	Cognitive impairment in Asian patients with heart failure: prevalence, biomarkers, clinical correlates, and outcomes. European Journal of Heart Failure, 2019, 21, 688-690.	2.9	16
282	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure, 2020, 22, 1586-1597.	2.9	16
283	Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 681-684.	2.9	16
284	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 782-790.	2.9	16
285	Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080.	2.2	16
286	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. Heart, 2016, 102, 1464-1471.	1.2	15
287	Defining a â€~frequent admitter' phenotype among patients with repeat heart failure admissions. European Journal of Heart Failure, 2019, 21, 311-318.	2.9	15
288	Genetic risk and atrial fibrillation in patients with heart failure. European Journal of Heart Failure, 2020, 22, 519-527.	2.9	15

#	Article	IF	CITATIONS
289	Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular Diabetology, 2021, 20, 159.	2.7	15
290	Circulating levels and prognostic cutâ€offs of sST2, hsâ€cTnT, and NTâ€proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	1.4	15
291	Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. Diabetes and Metabolism, 2022, 48, 101367.	1.4	15
292	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. European Journal of Heart Failure, 2022, 24, 1614-1622.	2.9	15
293	Function over form? Assessing the left atrium in heart failure. European Heart Journal, 2015, 36, 711-714.	1.0	14
294	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection FractionCLINICAL PERSPECTIVE. Circulation: Heart Failure, 2017, 10, e003534.	1.6	14
295	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 254, 203-209.	0.8	14
296	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2018, 121, 621-627.	0.7	14
297	Fat, Female, Fatigued. JACC: Heart Failure, 2018, 6, 710-713.	1.9	14
298	A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy. Communications Biology, 2020, 3, 697.	2.0	14
299	Heart failure with preserved ejection fraction diagnostic scores in an Asian population. European Journal of Heart Failure, 2020, 22, 1737-1739.	2.9	14
300	Natriuretic Peptide-Based Inclusion Criteria in a HeartÂFailure Clinical Trial. JACC: Heart Failure, 2020, 8, 359-368.	1.9	14
301	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 349-359.	1.9	14
302	Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction. Scientific Reports, 2022, 12, .	1.6	14
303	Chronic Indwelling Pleural Catheters Reduce Hospitalizations in Advanced Heart Failure with Refractory Pleural Effusions. Journal of Cardiac Failure, 2009, 15, S105.	0.7	13
304	Differences in Presentation, Management and Outcomes in Women and Men Presenting to an Emergency Department With Possible Cardiac Chest Pain. Heart Lung and Circulation, 2017, 26, 1282-1290.	0.2	13
305	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). American Journal of Cardiology, 2019, 124, 1912-1917.	0.7	13
306	Prediction of Survival in Asian Patients Hospitalized With Heart Failure: Validation of the OPTIMIZE-HF Risk Score. Journal of Cardiac Failure, 2019, 25, 571-575.	0.7	13

#	Article	IF	CITATIONS
307	Plasma <scp>D</scp> â€dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the <scp>COMMANDERâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 648-656.	2.9	13
308	Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. Clinical Chemistry, 2021, 67, 216-226.	1.5	13
309	Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006962.	0.9	13
310	Tissue factor cytoplasmic domain exacerbates post-infarct left ventricular remodeling via orchestrating cardiac inflammation and angiogenesis. Theranostics, 2021, 11, 9243-9261.	4.6	13
311	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. Korean Journal of Internal Medicine, 2016, 31, 1-14.	0.7	13
312	Association of Age, Sex, Body Size and Ethnicity with Electrocardiographic Values in Community-based Older Asian Adults. Heart Lung and Circulation, 2016, 25, 705-711.	0.2	12
313	Paradoxical Low-Gradient Aortic Stenosis. Journal of the American College of Cardiology, 2016, 67, 2447-2448.	1.2	12
314	Thymosin Betaâ€4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	1.6	12
315	Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART). BMC Cardiovascular Disorders, 2019, 19, 259.	0.7	12
316	Victims of Success in Failure. Circulation, 2020, 142, 1129-1131.	1.6	12
317	Design and baseline characteristics of the <scp>AMPLITUDEâ€O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€l receptor agonist. Diabetes, Obesity and Metabolism, 2021, 23, 318-323.	2.2	12
318	Association of sodiumâ€glucose cotransporterâ€2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the <scp>CVDâ€REAL</scp> 2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1431-1435.	2.2	12
319	Relationship Between Soluble Transferrin Receptor and Clinical Outcomes in Patients With Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study. Journal of Cardiac Failure, 2022, 28, 1255-1263.	0.7	12
320	Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis. Heart Failure Reviews, 2022, 27, 1933-1955.	1.7	12
321	Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from <scp>REPORTâ€HF</scp> (International Registry to assess <scp>mEdical</scp> Practice with) Tj ETQq1 1 0.784 Failure. 2022	314 rgBT 2.9	/Overlock 10
322	The Mitral Annular Middiastolic Velocity Curve: Functional Correlates and Clinical Significance in Patients with Left Ventricular Hypertrophy. Journal of the American Society of Echocardiography, 2008, 21, 165-170.	1.2	11
323	Impact of aortic root size on left ventricular afterload and stroke volume. European Journal of Applied Physiology, 2016, 116, 1355-1365.	1.2	11
324	Chronic obstructive pulmonary disease and βâ€blocker treatment in Asian patients with heart failure. ESC Heart Failure, 2018, 5, 297-305.	1.4	11

#	Article	IF	CITATIONS
325	Circulating neuregulin1â€Î² in heart failure with preserved and reduced left ventricular ejection fraction. ESC Heart Failure, 2020, 7, 445-455.	1.4	11
326	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	0.8	11
327	Methods and rationale of the DISCOVER CKD global observational study. CKJ: Clinical Kidney Journal, 2021, 14, 1570-1578.	1.4	11
328	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. Global Heart, 2020, 15, 44.	0.9	11
329	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC: Heart Failure, 2022, 10, 1-11.	1.9	11
330	Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICEâ€ASIAâ€HF). ESC Heart Failure, 2016, 3, 71-76.	1.4	10
331	Comparison of health state values derived from patients and individuals from the general population. Quality of Life Research, 2017, 26, 3353-3363.	1.5	10
332	Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. ESC Heart Failure, 2020, 7, 996-1006.	1.4	10
333	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. Current Heart Failure Reports, 2021, 18, 284-289.	1.3	10
334	The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. Global Heart, 2021, 16, 22.	0.9	10
335	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart, 2022, 108, 1200-1208.	1.2	10
336	Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure, 2022, 24, 1532-1544.	2.9	10
337	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circulation: Heart Failure, 2022, 15, .	1.6	10
338	Sex and Cardiovascular Risk. Circulation, 2012, 126, 913-915.	1.6	9
339	Impact of the joint association between sex, age and diabetes on long-term mortality after acute myocardial infarction. BMC Public Health, 2015, 15, 308.	1.2	9
340	Influence of Ethnicity, Age, and Time on Sex Disparities in Longâ€Term Causeâ€Specific Mortality After Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	9
341	Atrial Fibrillation in Heart Failure â^—. JACC: Heart Failure, 2017, 5, 575-577.	1.9	9
342	The women's heart health programme: a pilot trial of sex-specific cardiovascular management. BMC Women's Health, 2018, 18, 56.	0.8	9

#	Article	IF	CITATIONS
343	Cornell product is an ECG marker of heart failure with preserved ejection fraction. Heart Asia, 2019, 11, e011108.	1.1	9
344	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. Journal of the Chinese Medical Association, 2019, 82, 447-451.	0.6	9
345	Patientâ€reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence. ESC Heart Failure, 2020, 7, 2051-2062.	1.4	9
346	Universal Definition and Classification of Heart Failure: Is It universal? Does It Define Heart Failure?. Journal of Cardiac Failure, 2021, 27, 509-511.	0.7	9
347	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <scp>HEAAL</scp> trial. European Journal of Heart Failure, 2021, 23, 1477-1484.	2.9	9
348	Association of Cardiovascular Health Metrics With Risk of Transition to Hypertension in Non-Hypertensive Young Adults. American Journal of Hypertension, 2022, 35, 858-866.	1.0	9
349	Preface. Heart Failure Clinics, 2014, 10, xv.	1.0	8
350	Nâ€ŧerminal proâ€Bâ€ŧype natriuretic peptide and prognosis in <scp>Caucasian</scp> vs. <scp>Asian</scp> patients with heart failure. ESC Heart Failure, 2018, 5, 279-287.	1.4	8
351	High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. International Journal of Cardiology, 2019, 282, 93-98.	0.8	8
352	Ethnic differences in quality of life and its association with survival in patients with heart failure. Clinical Cardiology, 2020, 43, 976-985.	0.7	8
353	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. European Journal of Preventive Cardiology, 2021, 28, 937-945.	0.8	8
354	Clinical Outcome Predictions for the VerlCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure, 2021, 27, 949-956.	0.7	8
355	Defining changes in physical limitation from the patient perspective: insights from the <scp>VITALITYâ€HFpEF</scp> randomized trial. European Journal of Heart Failure, 2022, , .	2.9	8
356	Teaching cardiac auscultation without patient contact. Medical Education, 2004, 38, 1184-1185.	1.1	7
357	Heart Failure in Women: Risk Across a Woman's Adult Life. Journal of Cardiac Failure, 2017, 23, 379-381.	0.7	7
358	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. Diabetes, Obesity and Metabolism, 2019, 21, 261-266.	2.2	7
359	Longitudinal Community-Based Study of QT Interval and Mortality in Southeast Asians. PLoS ONE, 2016, 11, e0154901.	1.1	7
360	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	1.6	7

#	Article	IF	CITATIONS
361	Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure. Frontiers in Immunology, 2022, 13, 817514.	2.2	7
362	Temporal trends and patterns of infective endocarditis in a Chinese population: A territory-wide study in Hong Kong (2002–2019). The Lancet Regional Health - Western Pacific, 2022, 22, 100417.	1.3	7
363	Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a metaâ€analysis. ESC Heart Failure, 2022, 9, 2753-2761.	1.4	7
364	Impact Of Sex On Clinical Characteristics And In-Hospital Outcomes In A Multi-Ethnic Southeast Asian Population Of Patients Hospitalized For Acute Heart Failure. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2014, 22, 8.	0.0	6
365	Impact of stock market volatility on mortality and cardiovascular events. International Journal of Cardiology, 2016, 223, 318-319.	0.8	6
366	Membrane Proteomics of Impaired Energetics and Cytoskeletal Disorganization in Elderly Diet-Induced Diabetic Mice. Journal of Proteome Research, 2017, 16, 3504-3513.	1.8	6
367	Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. European Journal of Heart Failure, 2017, 19, 1732-1735.	2.9	6
368	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. ESC Heart Failure, 2020, 7, 1419-1429.	1.4	6
369	Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211.	1.9	6
370	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, 2022, 111, 50-59.	1.5	6
371	Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021414.	1.6	6
372	Ventricular TLR4 Levels Abrogate TLR2-Mediated Adverse Cardiac Remodeling upon Pressure Overload in Mice. International Journal of Molecular Sciences, 2021, 22, 11823.	1.8	6
373	What Is Normal in HFNEF?. JACC: Heart Failure, 2014, 2, 541-543.	1.9	5
374	Minding the Gap in Heart Failure. JACC: Heart Failure, 2016, 4, 50-54.	1.9	5
375	the Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial. Journal of Cardiac Failure, 2018, 24, 812.	0.7	5
376	Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction. American Journal of Cardiology, 2018, 122, 999-1007.	0.7	5
377	Prescription patterns of antiâ€diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. European Journal of Heart Failure, 2019, 21, 685-688.	2.9	5
378	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563.	1.5	5

#	Article	IF	CITATIONS
379	The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. European Journal of Heart Failure, 2021, 23, 1872-1874.	2.9	5
380	Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2022, 118, 2478-2487.	1.8	5
381	Electrocardiographic Criteria for Left Ventricular Hypertrophy in Asians Differs from Criteria Derived from Western Populations–Community-based Data from an Asian Population. Annals of the Academy of Medicine, Singapore, 2015, 44, 274-83.	0.2	5
382	Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure. Heart Failure Reviews, 2018, 23, 461-468.	1.7	4
383	Heart failure with midâ€range ejection fraction: causes and consequences. European Journal of Heart Failure, 2018, 20, 660-662.	2.9	4
384	An East–West comparison of self-care barriers in heart failure. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 615-622.	0.4	4
385	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIANâ€HF registry. European Journal of Heart Failure, 2020, 22, 751-754.	2.9	4
386	Association between body surface area and prescribed doses of guidelineâ€directed medications among international patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 754-758.	2.9	4
387	Heart failure or heart success?. Cardiovascular Research, 2021, 117, e29-e34.	1.8	4
388	Machine learning versus classic electrocardiographic criteria for the detection of echocardiographic left ventricular hypertrophy in a pre-participation cohort. Kardiologia Polska, 2021, 79, 654-661.	0.3	4
389	Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease. Value in Health, 2022, 25, 451-460.	0.1	4
390	How to Incorporate Sex and Gender Into the Design of Cardiovascular Clinical Trials. Circulation, 2022, 145, 499-501.	1.6	4
391	Biomarker changes as surrogate endpoints in earlyâ€phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2107-2118.	1.4	4
392	Prevalence and Prognostic Significance of Frailty in Asian Patients With HeartÂFailure. JACC Asia, 2021, 1, 303-313.	0.5	4
393	Women and Heart Failure: An Emerging Venus-Mars Concept. Current Cardiovascular Risk Reports, 2013, 7, 212-216.	0.8	3
394	Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. Journal of Hypertension, 2014, 32, 174-180.	0.3	3
395	Medical Podcasting and <i>Circulation on the Run</i> . Circulation, 2017, 136, 513-515.	1.6	3
396	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications, 2018, 32, 1035-1039.	1.2	3

#	Article	IF	CITATIONS
397	Empagliflozin and Heart Failure. Circulation, 2019, 139, 2831-2834.	1.6	3
398	The diabetes-atrial fibrillation paradox. Heart, 2019, 105, 893.1-893.	1.2	3
399	Cardiac and renal biomarkers in recreational runners following a 21 km treadmill run. Clinical Cardiology, 2020, 43, 1443-1449.	0.7	3
400	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proofâ€ofâ€concept study. ESC Heart Failure, 2020, 7, 4267-4276.	1.4	3
401	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIANâ€HF Registry. Journal of the American Heart Association, 2021, 10, e017932.	1.6	3
402	Subclinical vasculopathy and skeletal muscle metrics in the singapore longitudinal ageing study. Aging, 2021, 13, 14768-14784.	1.4	3
403	The Relationship among Carotid Artery Remodeling, Cardiac Geometry, and Serum N-Terminal Pro–B-Type Natriuretic Peptide Level in Asymptomatic Asians: Sex-Differences and Longitudinal GEE Study. PLoS ONE, 2015, 10, e0131440.	1.1	3
404	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. Journal of Diabetes and Its Complications, 2021, 35, 108077.	1.2	3
405	Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort. Advances in Therapy, 2022, 39, 1432-1445.	1.3	3
406	Developing a core outcome set for patient-reported symptom monitoring to reduce hospital admissions for patients with heart failure. European Journal of Cardiovascular Nursing, 2022, 21, 830-839.	0.4	3
407	Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2022, 9, 857360.	1.1	3
408	Response to Letter Regarding Article, "Cardiac Structure and Ventricular–Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota― Circulation, 2007, 116, .	1.6	2
409	Anti-Remodeling Effects of Chronic Phosphodiesterase-Type-5 Inhibition Are Dependent on Impaired cGMP-Dependent Protein Kinase Signaling. Journal of Cardiac Failure, 2009, 15, S3.	0.7	2
410	Natriuretic peptides, gender and cardiovascular risk: What is the link?. Maturitas, 2012, 71, 89-91.	1.0	2
411	Physicians' Perception of the Patient Care Pathway for Acute Heart Failure in Asian Countries: Implications for Resource Allocation, Preventive Strategies and Clinical Trial Design. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2014, 22, .	0.0	2
412	Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes. European Journal of Heart Failure, 2018, 20, 821-822.	2.9	2
413	Choosing a Career in Heart Failure. Circulation: Heart Failure, 2019, 12, e006026.	1.6	2
414	Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1935-1940.	0.7	2

#	Article	IF	CITATIONS
415	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. American Heart Journal, 2022, 243, 11-14.	1.2	2
416	Association of Female Menopause With Atrioventricular Mechanics and Outcomes. Frontiers in Cardiovascular Medicine, 2022, 9, 804336.	1.1	2
417	Comments on "the impact of SARS on medical house staff …― Journal of General Internal Medicine, 2005, 20, 973-973.	1.3	1
418	Diastolic Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction: A Population Based Study. Journal of Cardiac Failure, 2006, 12, S4.	0.7	1
419	Invasive Characterization of Hemodynamic Events during Diastasis in Patients with Structural Heart Disease. Journal of Cardiac Failure, 2006, 12, S20-S21.	0.7	1
420	Matrix Metalloproteinases and Their Endogenous Inhibitors: Association with Ventricular Remodeling, Diastolic Dysfunction and Heart Failure in the Community. Journal of Cardiac Failure, 2006, 12, S32.	0.7	1
421	Does a Normal BNP Exclude Heart Failure with Preserved Ejection Fraction?. Journal of Cardiac Failure, 2009, 15, S111.	0.7	1
422	PREFERENCE FOR SYMPTOM VERSUS SURVIVAL IMPROVEMENT AMONG ASIAN PATIENTS WITH HEART FAILURE. Journal of the American College of Cardiology, 2012, 59, E1917.	1.2	1
423	Random Plasma Glucose Levels and Cardiovascular Risk. JAMA Cardiology, 2016, 1, 823.	3.0	1
424	A Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure: The COMMANDER HF study. Journal of Cardiac Failure, 2018, 24, 811.	0.7	1
425	APPLICATION OF THE H2FPEF-SCORE TO A GLOBAL CLINICAL TRIAL OF PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE TOPCAT TRIAL. Journal of the American College of Cardiology, 2019, 73, 912.	1.2	1
426	Discussion forum response to Canepa et al. European Heart Journal, 2019, 40, 705-706.	1.0	1
427	Heart Disease in Women: Where Are We Now and What is The Future?. Heart Lung and Circulation, 2021, 30, 1-2.	0.2	1
428	QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction. Cardiology Journal, 2021, 28, 166-169.	0.5	1
429	BASELINE CARDIAC TROPONIN T, CLINICAL OUTCOMES AND VERICIGUAT TREATMENT EFFECT IN HEART FAILURE WITH REDUCED EJECTION FRACTION STUDY: INSIGHTS FROM THE VICTORIA TRIAL. Journal of the American College of Cardiology, 2021, 77, 565.	1.2	1
430	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. Journal of Cardiac Failure, 2021, 27, 1456-1461.	0.7	1
431	Concomitant Hepatorenal Dysfunction and Malnutrition in Valvular Heart Surgery: Longâ€Term Prognostic Implications for Death and Heart Failure. Journal of the American Heart Association, 2022, 11, e024060.	1.6	1
432	Heart failure with normal LVEF in BIOSTAT-CHF. International Journal of Cardiology, 2022, 364, 85-90.	0.8	1

#	Article	IF	CITATIONS
433	Clinical implications of the universal definition for the prevention and treatment of heart failure. Clinical Cardiology, 2022, 45, .	0.7	1
434	Sex, fat and the heart: it's all in the waist. European Journal of Heart Failure, 2022, 24, 1371-1376.	2.9	1
435	Cardiac Volumes in Patients with Heart Failure and Preserved Ejection Fraction: A Population Based Study. Journal of Cardiac Failure, 2006, 12, S23.	0.7	0
436	Depressed Myocardial Contractility Despite Normal Chamber Systolic Function in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2008, 14, S14-S15.	0.7	0
437	Prevalence and Prognostic Significance of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: A Population-Based Study. Journal of Cardiac Failure, 2008, 14, S16-S17.	0.7	0
438	Aging Versus Hypertension in Heart Failure with Preserved Ejection Fraction: Insights from Murine Models. Journal of Cardiac Failure, 2008, 14, S31-S32.	0.7	0
439	Impact of Aging on Pulmonary Hemodynamics in the General Population. Journal of Cardiac Failure, 2008, 14, S82-S83.	0.7	0
440	Reduced Metabolic Exercise Capacity Predicts Death and Heart Failure in Minimally Symptomatic Patients with Obstructive Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2009, 15, S91-S92.	0.7	0
441	Isolating the Renal Venous System from Systolic Reflux in Severe Tricuspid Regurgitation Using Transcatheter Valves. Journal of Cardiac Failure, 2009, 15, S50.	0.7	0
442	Pulmonary Artery Systolic Pressure Is an Independent Predictor of Exercise Capacity in Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2009, 15, S20.	0.7	0
443	Ethnic Differences in Risk Prediction for Heart Failure Rehospitalization. Journal of Cardiac Failure, 2011, 17, S68.	0.7	0
444	Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES). Journal of Cardiac Failure, 2014, 20, S39.	0.7	0
445	ETHNICITY AND SEX-SPECIFIC ECHOCARDIOGRAPHIC AND ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY: COMMUNITY-BASED DATA FROM AN ASIAN POPULATION. Journal of the American College of Cardiology, 2014, 63, A1093.	1.2	0
446	Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	1.6	0
447	Causes of Death Among Patients with and without Dlabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry. Journal of Cardiac Failure, 2018, 24, S69.	0.7	0
448	Left Atrial Myopathy in Heart Failure with Preserved Ejection Fraction: Insights from the PROMIS-HFpEF Study. Journal of Cardiac Failure, 2019, 25, S43.	0.7	0
449	Comparison of HeartLogic Heart Failure Diagnostic Sensor Measurements and Alerts between Patients with CRT-D and ICD Devices. Journal of Cardiac Failure, 2019, 25, S186.	0.7	0
450	INITIATION OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS OTHER GLUCOSE LOWERING DRUGS AND RISK OF HOSPITALIZATION FOR HEART FAILURE AND DEATH IN PATIENTS WITH TYPE 2 DIABETES WITH REDUCED AND PRESERVED LEFT VENTRICULAR EJECTION FRACTION. Journal of the American College of Cardiology, 2019, 73, 1705.	1.2	0

#	Article	IF	CITATIONS
451	Reply in response to †Defining a "frequent admitter―phenotype among patients with repeat heart failure admissions'. European Journal of Heart Failure, 2020, 22, 385-386.	2.9	0
452	Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy. Journal of Cardiac Failure, 2020, 26, 1108-1109.	0.7	0
453	PO816CLINICAL CHARACTERISTICS AND EGFR AND UACR DISTRIBUTION ACCORDING TO THE 2012 KDIGO CKD CLASSIFICATION: A REPORT FROM THE US DISCOVER CKD COHORT. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	Ο
454	Scientists on the Spot: A fraction of wisdom on heart failure. Cardiovascular Research, 2021, 117, e114-e115.	1.8	0
455	Use of Telemetry and Plethysmography to Assess Respiratory Function in Conscious Rats with Bleomycin-Induced Lung Fibrosis. , 2019, , .		Ο
456	Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial― Circulation, 2022, 146, .	1.6	0